Dréan Antonin, Goldwirt Lauriane, Verreault Maïté, Canney Michael, Schmitt Charlotte, Guehennec Jeremy, Delattre Jean-Yves, Carpentier Alexandre, Idbaih Ahmed
a Inserm U 1127, CNRS UMR 7225 , Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM , Paris , France.
b Carthera SAS , Institut du Cerveau et de la Moelle épinière, ICM , Paris , France.
Expert Rev Neurother. 2016 Nov;16(11):1285-1300. doi: 10.1080/14737175.2016.1202761. Epub 2016 Jul 4.
Glioblastomas (GBM) are the most common and aggressive primary malignant brain tumors in adults. The blood brain barrier (BBB) is a major limitation reducing efficacy of anti-cancer drugs in the treatment of GBM patients. Areas covered: Virtually all GBM recur after the first-line treatment, at least partly, due to invasive tumor cells protected from chemotherapeutic agents by the intact BBB in the brain adjacent to tumor. The passage through the BBB, taken by antitumor drugs, is poorly and heterogeneously documented in the literature. In this review, we have focused our attention on: (i) the BBB, (ii) the passage of chemotherapeutic agents across the BBB and (iii) the strategies investigated to overcome this barrier. Expert commentary: A better preclinical knowledge of the crossing of the BBB by antitumor drugs will allow optimizing their clinical development, alone or combined with BBB bypassing strategies, towards an increased success rate of clinical trials.
胶质母细胞瘤（GBM）是成人中最常见且侵袭性最强的原发性恶性脑肿瘤。血脑屏障（BBB）是限制抗癌药物治疗GBM患者疗效的主要因素。涵盖领域：几乎所有GBM在一线治疗后都会复发，至少部分原因是侵袭性肿瘤细胞受到肿瘤邻近脑组织中完整血脑屏障的保护，免受化疗药物的作用。抗肿瘤药物通过血脑屏障的过程在文献中的记载较少且存在差异。在本综述中，我们重点关注了：（i）血脑屏障，（ii）化疗药物穿过血脑屏障的过程，以及（iii）为克服这一屏障而研究的策略。专家评论：对抗肿瘤药物穿过血脑屏障有更好的临床前了解，将有助于优化其临床开发，无论是单独使用还是与血脑屏障绕过策略联合使用，以提高临床试验的成功率。
